Display options
Cite
Mohamed NE, Gilbert F, Lee CT, et al. Pursuing Quality in the Application of Bladder Cancer Quality of Life Research. Bladder Cancer. 2016;2(2):139-149doi: 10.3233/BLC-160051.
Mohamed, N. E., Gilbert, F., Lee, C. T., Sfakianos, J., Knauer, C., Mehrazin, R., Badr, H., Wittmann, D., Downs, T., Berry, D., Given, B., Wiklund, P., & Steineck, G. (2016). Pursuing Quality in the Application of Bladder Cancer Quality of Life Research. Bladder cancer (Amsterdam, Netherlands), 2(2), 139-149. https://doi.org/10.3233/BLC-160051
Mohamed, N E, et al. "Pursuing Quality in the Application of Bladder Cancer Quality of Life Research." Bladder cancer (Amsterdam, Netherlands) vol. 2,2 (2016): 139-149. doi: https://doi.org/10.3233/BLC-160051
Mohamed NE, Gilbert F, Lee CT, Sfakianos J, Knauer C, Mehrazin R, Badr H, Wittmann D, Downs T, Berry D, Given B, Wiklund P, Steineck G. Pursuing Quality in the Application of Bladder Cancer Quality of Life Research. Bladder Cancer. 2016 Apr 27;2(2):139-149. doi: 10.3233/BLC-160051. PMID: 27376136; PMCID: PMC4927895.
Copy Download .nbib Format: NLM
Share it on

Bladder Cancer. 2016 Apr 27;2(2):139-149. doi: 10.3233/BLC-160051.

Pursuing Quality in the Application of Bladder Cancer Quality of Life Research.

Bladder cancer (Amsterdam, Netherlands)

N E Mohamed, F Gilbert, C T Lee, J Sfakianos, C Knauer, R Mehrazin, H Badr, D Wittmann, T Downs, D Berry, B Given, P Wiklund, G Steineck

Affiliations

  1. Department of Urology, Icahn School of Medicine at Mount Sinai , New York, NY, USA.
  2. Unaffiliated.
  3. Department of Urology, University of Michigan , Ann Arbor, MI, USA.
  4. Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai , New York, NY, USA.
  5. Department of Urology, University of Wisconsin , Madison, WI, USA.
  6. Dana-Farber Cancer Institute , Boston, MA, USA.
  7. Department of Medicine, Harvard Medical School, Dana-Farber Cancer Institute , Boston, MA, USA.
  8. Division of Clinical Cancer Epidemiology, Sahlgrenska universitetssjukhuset , Göteborg, Sweden.

PMID: 27376136 PMCID: PMC4927895 DOI: 10.3233/BLC-160051

Abstract

Patient-reported outcomes (PRO), including health-related quality of life (HRQOL) measures, represent important means for evaluating patients' health outcomes and for guiding health care decisions made by patients, practitioners, investigators, and policy makers. In spite of the large number of studies examining HRQOL in patients with bladder cancer, very few review articles investigated this topic. Because these review studies report mixed results, incorporating bladder cancer HRQOL measures into standard urological practice is not a viable option. In this non-systematic review of the literature and commentary we note some general concerns regarding PRO research, but our primary focus is on the HRQOL methodology within the context of two types of bladder cancer: muscle invasive and non-muscle invasive bladder cancer. Considering bladder cancer HRQOL as the interaction of four areas of the assessment process (i.e., what model of HRQOL to choose, what instruments are available to fit the choice, how interpretation of the resulting data fits the model, and how to derive some utility from the chosen model) and the two types of disease (i.e., muscle invasive and non-muscle invasive) may move us toward a better understanding of bladder cancer HRQOL. Establishing a useful model of perceived general health or specific symptoms is the first and most important step in developing the responsive bladder cancer HRQOL measures necessitated by clinical settings.

Keywords: Patient-reported outcomes; bladder cancer; conceptual model of quality of life; design and development of bladder cancer quality of life measures; health-related quality of life; muscle invasive bladder cancer; non-muscle invasive bladder cancer; quality of life assessments

References

  1. Cancer. 1985 Jan 1;55(1):72-6 - PubMed
  2. J Palliat Med. 2004 Feb;7(1):19-25 - PubMed
  3. J Urol. 2010 May;183(5):1764-9 - PubMed
  4. J Urol. 2014 Jan;191(1):48-53 - PubMed
  5. Qual Life Res. 2003 Sep;12(6):675-88 - PubMed
  6. Qual Life Res. 2010 May;19(4):539-49 - PubMed
  7. Qual Life Res. 2014 Dec;23(10):2651-61 - PubMed
  8. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD007617 - PubMed
  9. Support Care Cancer. 2010 Jun;18(6):699-706 - PubMed
  10. J Urol. 2004 Dec;172(6 Pt 1):2130-6 - PubMed
  11. Urol Oncol. 2015 Jul;33(7):331.e17-23 - PubMed
  12. Cancer Nurs. 1995 Oct;18(5):337-43 - PubMed
  13. Br J Urol. 1996 Sep;78(3):369-71 - PubMed
  14. Urol Oncol. 2015 Jan;33(1):19.e7-15 - PubMed
  15. Scand J Caring Sci. 2003 Jun;17(2):113-21 - PubMed
  16. Qual Life Res. 2014 Oct;23(8):2153-67 - PubMed
  17. Image J Nurs Sch. 1999;31(3):215-20 - PubMed
  18. Eur J Surg Oncol. 2016 Mar;42(3):343-60 - PubMed
  19. J Urol. 2002 Jul;168(1):168-74; discussion 174-5 - PubMed
  20. Interact J Med Res. 2014 Feb 11;3(1):e5 - PubMed
  21. Ann Oncol. 2006 May;17 Suppl 5:v106-12 - PubMed
  22. Adv Urol. 2012;2012:142135 - PubMed
  23. Value Health. 2011 Dec;14(8):978-88 - PubMed
  24. BJU Int. 2014 Jan;113(1):11-23 - PubMed
  25. Med Care. 1992 Jun;30(6):473-83 - PubMed
  26. Qual Life Res. 2002 May;11(3):193-205 - PubMed
  27. Cancer. 2005 Dec 1;104(11 Suppl):2565-76 - PubMed
  28. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 - PubMed
  29. BMC Med Res Methodol. 2010 Mar 18;10:22 - PubMed
  30. J Chronic Dis. 1987;40(6):635-40 - PubMed
  31. Urol Nurs. 2007 Feb;27(1):65-77; discussion 78-80 - PubMed
  32. J Clin Oncol. 1993 Mar;11(3):570-9 - PubMed
  33. J Psychosom Res. 1988;32(4-5):429-38 - PubMed
  34. J Clin Epidemiol. 1997 Mar;50(3):233-8 - PubMed
  35. Cancer. 1997 Oct 15;80(8):1518-24 - PubMed
  36. Urol Clin North Am. 2005 May;32(2):207-16 - PubMed
  37. J Clin Oncol. 2012 Apr 10;30(11):1227-34 - PubMed
  38. Support Care Cancer. 2013 May;21(5):1383-93 - PubMed
  39. Oncol Nurs Forum. 2001 Jun;28(5):847-54 - PubMed
  40. JAMA. 1995 Jan 4;273(1):59-65 - PubMed
  41. BMJ. 2006 Mar 4;332(7540):515-21 - PubMed
  42. Cancer. 2009 Sep 15;115(18 Suppl):4311-25 - PubMed
  43. Eur J Cancer Care (Engl). 2014 Mar;23(2):173-9 - PubMed
  44. Semin Oncol Nurs. 2010 Nov;26(4):243-58 - PubMed
  45. J Clin Oncol. 1998 Jan;16(1):139-44 - PubMed
  46. Urol Oncol. 2005 May-Jun;23(3):201-7 - PubMed
  47. Palliat Med. 2003 Jan;17(1):63-74 - PubMed
  48. J Behav Med. 1997 Apr;20(2):101-25 - PubMed
  49. BMJ. 2004 May 29;328(7451):1312-5 - PubMed
  50. Psychooncology. 2012 Jun;21(6):571-87 - PubMed
  51. J Behav Med. 2001 Aug;24(4):297-321 - PubMed
  52. J Behav Med. 1997 Aug;20(4):333-49 - PubMed
  53. Qual Life Res. 2013 Oct;22(8):1889-905 - PubMed
  54. Adv Urol. 2011;2011:715892 - PubMed
  55. Oncol Nurs Forum. 2004 Nov 16;31(6):1105-17 - PubMed
  56. Expert Rev Anticancer Ther. 2013 Jun;13(6):661-8 - PubMed
  57. Exp Gerontol. 2014 Nov;59:74-80 - PubMed
  58. Cancer. 2007 May 1;109(9):1756-62 - PubMed
  59. J Nurs Scholarsh. 2005;37(4):336-42 - PubMed
  60. J Urol. 1996 Apr;155(4):1221-6 - PubMed
  61. Expert Rev Anticancer Ther. 2013 Jun;13(6):639-40 - PubMed
  62. Health Qual Life Outcomes. 2012 Nov 16;10:134 - PubMed
  63. Health Qual Life Outcomes. 2003 Dec 16;1:79 - PubMed

Publication Types